Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247

Benzinga Newsdesk www.benzinga.com Neutral 61.4%

Neg 0% Neu 61.4% Pos 0%

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.